Liver disease expert claims A ‘last ditch effort’ to eliminate hepatitis Cbecause Spain is one of the countries best equipped to achieve this goal, according to the recommendations set by the World Health Organization (WHO) for 2030.
This was revealed at the 15th “Multidisciplinary Open Class in Hepatology” organized by Gilead Sciences in Santander. During this meeting, experts assured that the key to meeting this challenge is to continue promoting the commitment to innovation and to continue promoting the strategy to eliminate viral hepatitis in Spain.
As Aula Abierta co-coordinator Dr. Javier Crespo from the Marqués de Valdecilla University Hospital in Santander explains, “This year the gathering More than 150 experts It is precisely when we have the ability to eliminate the C virus. There is nothing we can do to eliminate the hepatitis C virus, but we must continue to move forward to achieve this goal, complete the work we have left and make Spain one of the first countries in the world to achieve this goal. ”
Liver disease remains a global health problem in Spain.Although more than 164,502 people with hepatitis C have been treated, with a cure rate of approximately 95%, it is important to continue as it is estimated that More than 76,000 people in Spain are actively infected with C virus22,500 of whom were unaware of their diagnosis.
Innovation and training
In this sense, Marta Velázquez, Senior Business Unit and Director of Hepatology Business at Gilead Sciences, insists that “Gilead’s commitment and efforts are not only directed towards the development of innovative medicines or the training of health professionals, but also towards the implementation of recommendations to scientific associations, health Institutions and NGOs offer projects and scholarships that make it possible to eliminate HIV in Spain. For 20 years we have been on the front lines of the fight against the epidemic Changing care for patients with hepatitis B We are committed to tackling hepatitis D. “
Regarding the news about this conference, Dr. José Luis Calleja from the University Hospital of Puerta Hierro in Madrid and co-coordinator of this conference explained: “By organizing this event, we sought to select the most relevant topics in the field of hepatology, This therefore serves as an attractive forum for debate among participants. Always with this aim in mind Review of advances in treatment and diagnosis The most important in our profession. For this reason, current topics such as hepatitis D have been included, as important advances have been made in its diagnosis and treatment. “
Laiga-C
In this edition, pathologies such as drug-induced liver injury (DILI) or Wilson’s disease, metabolic hepatic steatosis (Masld, formerly known as non-alcoholic fatty liver disease), alcohol-related hepatic steatosis (ALD), and metabolic dysfunction and alcohol-induced hepatic steatosis (MetALD).
As part of this ongoing training, the third Lega-C, led by Gilead, was also held in Santander on October 20 and 21, where the current situation and challenges were discussed Research in the areas of ALD, MALD and viral hepatitis B and D.
As Dr. Calleja points out, the purpose of this appointment “is not only to understand what research projects have been carried out recently in the field, but also to discover exactly what unmet needs they have without being the subject of research”.